Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial

Trial Profile

Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Corticosteroid-induced osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 06 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top